A stark contrast is emerging within Ireland’s healthcare system: while clinical research activity is experiencing promising growth, patients suffering from rare diseases are facing increasingly severe delays in accessing newly approved treatments. Recent data from the Irish Pharmaceutical Healthcare Association (IPHA) reveals that patients in Ireland now wait an average of 801 days to access rare disease medicines following European regulatory approval.
The Growing Access Gap
The 801-day wait time represents a sharp deterioration from previous years and sits significantly higher than the EU average. Crucially, of the 66 rare disease medicines approved by the European Medicines Agency (EMA) between 2021 and 2024, only 27% are currently reimbursed and publicly available to patients in Ireland. Patient advocacy groups have expressed mounting frustration over structural inefficiencies in the national pricing and reimbursement process that continue to delay life-changing therapies.
Encouraging Clinical Trial Growth
Conversely, the life sciences sector in Ireland is witnessing a notable uptick in clinical research. The IPHA reports that industry-sponsored clinical trials rose from 41 in 2023 to 73 in 2025. This growth signals strong international confidence in Ireland's research capabilities and clinical infrastructure.
However, industry bodies warn that Ireland still lags behind peer nations like Denmark, which initiated more than double the number of clinical trials during the same period. Furthermore, Ireland is currently ranked as the slowest EU member state for regulatory setup times, taking an average of 213 days to ready a clinical trial site.
The Path Forward
While the newly signed Framework Agreements aim to streamline the reimbursement process over the coming years, stakeholders are heavily lobbying for immediate systemic reforms. Achieving faster access to rare disease treatments and streamlining clinical trial activations are widely viewed as critical imperatives to ensure Irish patients do not fall further behind their European counterparts.
